SLC7A5 and neoplasm: Therefore, to develop therapeutic tools to inhibit LAT1, more tumor-specific drug delivery methods (e.g., drug-conjugated antibodies, liposome-encapsulated drugs, and improvement of the tumor microenvironment) should be utilized for future clinical applications.